Apotex: Amgen Attempting To Obtain 'Undeserved' Profits
This article was originally published in Scrip
A preliminary injunction (PI) Amgen Inc. won this past December from a district court blocking Toronto-based Apotex Inc. from marketing its biosimilar version of the California biotech giant's long-acting human granulocyte colony-stimulating factor Neulasta (pegfilgrastim) for 180 days after the FDA licenses it is an "undisguised ploy to get an extra six months of undeserved monopoly profits based on a crabbed reading" of the Biologics Price Competition and Innovation Act (BPCIA), the latter company asserted in new court documents.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.